Second Sight Medical Products, Inc. (EYES) to Release Earnings on Tuesday
Second Sight Medical Products, Inc. (NASDAQ:EYES) will be releasing its earnings data after the market closes on Tuesday, October 31st. Analysts expect Second Sight Medical Products to post earnings of ($0.14) per share for the quarter.
Second Sight Medical Products (NASDAQ:EYES) last announced its quarterly earnings results on Tuesday, August 1st. The medical device company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.01. The business had revenue of $2.24 million during the quarter, compared to analysts’ expectations of $1.43 million. Second Sight Medical Products had a negative net margin of 646.89% and a negative return on equity of 168.49%. The firm’s revenue for the quarter was up 124.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.17) EPS. On average, analysts expect Second Sight Medical Products to post $-0.55 EPS for the current fiscal year and $-0.52 EPS for the next fiscal year.
Shares of Second Sight Medical Products, Inc. (EYES) opened at 1.12 on Tuesday. The stock’s market cap is $63.61 million. Second Sight Medical Products, Inc. has a 12 month low of $0.90 and a 12 month high of $3.51. The firm’s 50-day moving average is $1.16 and its 200 day moving average is $1.17.
A hedge fund recently raised its stake in Second Sight Medical Products stock. Vanguard Group Inc. raised its position in shares of Second Sight Medical Products, Inc. (NASDAQ:EYES) by 0.7% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 843,462 shares of the medical device company’s stock after acquiring an additional 5,973 shares during the period. Vanguard Group Inc. owned approximately 1.50% of Second Sight Medical Products worth $1,062,000 as of its most recent filing with the Securities & Exchange Commission. 13.07% of the stock is owned by institutional investors and hedge funds.
EYES has been the topic of a number of analyst reports. Zacks Investment Research upgraded shares of Second Sight Medical Products from a “sell” rating to a “hold” rating in a research report on Wednesday, September 13th. HC Wainwright reiterated a “buy” rating and set a $5.00 price objective on shares of Second Sight Medical Products in a research report on Thursday, July 6th.
About Second Sight Medical Products
Second Sight Medical Products, Inc is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight.
Receive News & Ratings for Second Sight Medical Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products Inc. and related companies with MarketBeat.com's FREE daily email newsletter.